Loading clinical trials...
Loading clinical trials...
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO AND OXYCODONE CONTROLLED MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Conditions
Interventions
tanezumab 10 mg
tanezumab 5 mg
+2 more
Locations
112
United States
Achieve Clinical Research
Birmingham, Alabama, United States
Alabama Orthopaedic Clinics, PC
Mobile, Alabama, United States
Horizon Research Group, Inc.
Mobile, Alabama, United States
Arizona Research Center, Inc.
Phoenix, Arizona, United States
Osteoporosis Medical Center
Beverly Hills, California, United States
Med Frontier Clinical Research
Buena Park, California, United States
Start Date
October 30, 2009
Primary Completion Date
December 13, 2010
Completion Date
February 4, 2011
Last Updated
May 14, 2021
NCT07153471
NCT07351968
NCT06747494
NCT06381791
NCT07327931
NCT06906939
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions